ITeos to Participate in Upcoming Investor Conferences
ITeos to Participate in Upcoming Investor Conferences
A live webcast of the conference presentation will be available on the Investors section of the company's website at . An archived replay will be available for approximately 30 days following the presentation.WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:
馬薩諸塞州沃特敦和比利時戈斯利，2024年11月26日（環球新聞網）-- iTeos Therapeutics, Inc.（納斯達克：ITOS），一家處於臨床階段的生物製藥公司，正在開創一代新型免疫腫瘤治療藥物，今天宣佈公司管理層將參加即將於12月舉行的兩個會議：
7Th Annual Evercore HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: Tuesday, December 3, 2024
Time: 9:35 AM ET
Location: Coral Gables, FL
7第 屆Evercore HealthCONx會議
形式：爐邊聊天和一對一投資者會議
日期：2024年12月3日，星期二
時間：美國東部時間上午9:35
地點：佛羅里達州珊瑚泉
Piper Sandler 36th Annual Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, December 4, 2024
Time: 11:30 AM ET
Location: New York, NY
派傑投資 36th 年度醫療會議
形式：爐邊聊天和一對一投資者會議
日期：2024年12月4日，星期三
時間：東部時間11:30
地點：紐約，NY
A live webcast of the conference presentation will be available on the Investors section of the company's website at . An archived replay will be available for approximately 30 days following the presentation.
會議演示的現場直播將可在公司網站的投資者部分查看。演示結束後，錄像回放將可用大約30天。
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company's innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
關於iTeos Therapeutics, Inc.
iTeos Therapeutics是一家臨床階段的生物製藥公司，致力於開發新一代免疫腫瘤治療藥物，服務於患者。iTeos Therapeutics利用其對腫瘤免疫學和免疫抑制途徑的深刻理解，設計新的候選藥物，以恢復對癌症的免疫反應。公司的創新管線包括三個臨床階段的項目，針對新的、經過驗證的免疫抑制途徑，旨在優化藥理特性以改善臨床結果，包括TIGIT/CD226軸和腺苷途徑。iTeos Therapeutics總部位於馬薩諸塞州沃特鎮，並在比利時的戈塞利斯設有研究中心。
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at . The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
信息的互聯網發佈
iTeos定期在其網站的「投資者」部分發布對投資者可能很重要的信息。該公司鼓勵投資者和潛在投資者定期查看我們的網站，以獲取關於iTeos的重要信息。
For further information, please contact:
如需更多信息，請聯繫：
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
投資者聯繫人：
卡爾·毛赫
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
媒體聯繫人：
media@iteostherapeutics.com
